Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism
2017
Abstract The cause of nonlinear pharmacokinetics (PK) (more than dose-proportional increase in exposure) of a urea derivative under development (compound A: anionic compound [pKa: 4.4]; LogP: 6.5; and plasma protein binding: 99.95%) observed in a clinical trial was investigated. Compound A was metabolized by CYP3A4, UGT1A1, and UGT1A3 with unbound K m of 3.3-17.8 μmol/L. OATP1B3-mediated uptake of compound A determined in the presence of human serum albumin (HSA) showed that unbound K m and V max decreased with increased HSA concentration. A greater decrease in unbound K m than in V max resulted in increased uptake clearance (V max /unbound K m ) with increased HSA concentration, the so-called albumin-mediated uptake. At 2% HSA concentration, unbound K m was 0.00657 μmol/L. A physiologically based PK model assuming saturable hepatic uptake nearly replicated clinical PK of compound A. Unbound K m for hepatic uptake estimated from the model was 0.000767 μmol/L, lower than the in vitro unbound K m at 2% HSA concentration, whereas decreased K m with increased concentration of HSA in vitro indicated lower K m at physiological HSA concentration (4%-5%). In addition, unbound K m values for metabolizing enzymes were much higher than unbound K m for OATP1B3, indicating that the nonlinear PK of compound A is primarily attributed to saturated OATP1B3-mediated hepatic uptake of compound A.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
31
References
25
Citations
NaN
KQI